Porcine implant for T1 approved for use in Russia
Living Cell Technologies announced that its Diabecell porcine implant for people with Type 1 diabetes as well as xenotransplantation has been approved for use in
Living Cell Technologies announced that its Diabecell porcine implant for people with Type 1 diabetes as well as xenotransplantation has been approved for use in
Diamyd is forging ahead with a Phase III human trial of DiaPrevent, a potentially new treatment that can stop or slow the destruction of insulin-producing
Eli Lilly and MacroGenics announced that they have suspended phase III trials of Protégé, a drug designed to address the autoimmune component in people with
Regarding the discontinuation of Novo Nordisk’s Mixtard30, only the Mixtard30 InnoLet is being discontinued — the InnoLet device will still be available with two other
Victoza (liraglutide) is an injectable medicine for people with type 2 diabetes. Today, as part of its Single Technology Appraisal (STA) the National Institute forHealth
From a talk given at the UK launch of the new Type 2 treatment given by Viggo Birch, vice president and managing director, Novo Nordisk
NICE has issued its Final Appraisal Determination (FAD) on the use of Victoza (liraglutide) for people with type 2 diabetes in the UK, the only
Survey finds increased need for more medicines like Byetta and Januvia Initially reported in July 2009, a survey, “A Clinician and Payer Perspective on Changing
From a talk given by Professor Anthony Barnett (Professor of Medicine and Honorary Consultant Physician at the University of Birmingham and Heart Of England NHS